EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cardiovascular adverse events associated with antibody-drug conjugates (ADCs): a pharmacovigilance study based on the FAERS database

Kardiovaskuläre unerwünschte Ereignisse im Zusammenhang mit Antikörper-Wirkstoff-Konjugaten (ADCs): pharmakovigilanzbasierte Studie mit FAERS-Daten

PingPing Long, Siyu Li, Lingyun Pan, Yuanqiang Wang, Wanyi Chen, Xiaoxiao Wang

Frontiers in Pharmacology · 03.05.2024 · 15

DOI: 10.3389/fphar.2024.1378010 ↗

Auf einen Blick

In FAERS wurden unter ADC-Therapie kardiovaskuläre unerwünschte Ereignisse ausgewertet. Die Meldungen deuteten auf eine erhöhte kardiovaskuläre Toxizität hin.

Fragestellung

Welche kardiovaskulären unerwünschten Ereignisse sind in FAERS mit ADCs assoziiert?

Methode

Auswertung von FAERS-Meldungen mit OpenVigil 2.1; Berichte von der Markteinführung bis zum zweiten Quartal 2023; Einteilung in 14 SMQ-Kategorien; Berechnung von ROR und PRR.

Ergebnisse

Es wurden 1863 mit kardiovaskulären Ereignissen assoziierte AEs identifiziert. Häufig waren Herzinsuffizienz (n = 277) sowie embolische und thrombotische venöse Ereignisse (n = 446).

Einschränkungen

Pharmakovigilanzdaten ohne Kausalitätsnachweis; viele Fälle waren als unbekannt klassifiziert.

Schlussfolgerung der Autor:innen

Die Analyse der FAERS-Daten liefert Hinweise auf eine Assoziation zwischen ADC-Anwendung und kardiovaskulären unerwünschten Ereignissen; dafür sind Monitoring und Management erforderlich. Weitere Forschung ist nötig.

Kernaussagen

  • 1863 kardiovaskuläre AEs bei ADC-Therapie in FAERS
  • Häufig: Herzinsuffizienz und venöse thrombotische Ereignisse
  • Hinweis auf erhöhte kardiovaskuläre Toxizität

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 03.05.2024. Verfasst von PingPing Long und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy and Bioengineering, Chongqing University of Technology, Chongqing, China. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

As a novel drug formulation, antibody drug conjugates (ADCs) are widely used in various types of cancer. However, clinically, there is a lack of attention to the CVD produced by them, as well as a lack of research on the real-world situation. Using the Food and Drug Administration Adverse Event Reporting System (FAERS) database, to ensure its clinical safety application, we analyzed post-marketing data on antitumor ADCs to identify risk factors and drugs associated with the risk of cardiovascular events. Research design and methods We used OpenVigil 2.1 to conduct a database query for adverse events (AEs) reported to the FAERS database between the time the drug was launched and the second quarter of 2023. Cardiovascular adverse events (AEs) were grouped into fourteen narrow categories using the Standardized Medical Dictionary for Regulatory Activities (MedDRA) Queries (SMQs), and the reporting odds ratio (ROR) and the proportional reporting ratio (PRR) for reporting the association between different drugs and cardiovascular disease (CVD) risk were calculated.

Results

In the FAERS database, 1863 AEs associated with CVD we studied were identified in patients receiving ADC therapy. Most reports came from people aged ≥65, but a significant number of cases were found to be unknown. The number of patients with antibody-drug conjugates (ADCs)-related CVD cases aged <18 years, 18–64 years, and≥ 65 years was 52 (2.79%), 586 (31.45%), and 613 (32.90%), respectively. The proportion of female patients (834, 44.77%) was higher than that of male patients (752, 40.37%). Death (770 reports), disability (9 reports), Hospitalization initial or prolonged (407 reports), and life-threatening reactions (187 reports). Of the 770 deaths reported, 103 (31.7%) were associated with brentuximab vedotin, 10 (24.4%) with sacituzumab govitecan, 22 (19.3%) with enfortumab vedotin, and 35 (34.7%) with trastuzumab emtansine.49 (41.2%) cases were associated with polatuzumab vedotin, 62 (29%) with trastuzumab deruxtecan, 423 (54.3%) with gemtuzumab ozogamicin, and 66 (38.8%) with inotuzumab ozogamicin. In a disproportionate number of SMQS, cardiac failure ( n = 277) and embolic and thrombotic events, venous ( n = 446) were the most frequently reported CVD-related AEs in ADCs.

Conclusion

By mining the FAERS database, we provided relevant information on the association between ADC use and cardiovascular-associated AEs. ADCs were associated with increased cardiovascular toxicity, deserving distinct monitoring and appropriate management. Further research is needed to confirm these findings and assess causality.

Schlagwörter

Stichwörter der Autor:innen

FAERSadverse eventsantibody-drug conjugatecardiovascular toxicitydisproportionality analysis

Autor:innen und Institutionen

  • School of Pharmacy and Bioengineering, Chongqing University of Technology, Chongqing, China.
  • Department of Pharmacy, Chongqing University Cancer Hospital, Chongqing, China.

Zitieren

APA

Long, P., Li, S., Pan, L., Wang, Y., Chen, W., & Wang, X. (2024). Cardiovascular adverse events associated with antibody-drug conjugates (ADCs): a pharmacovigilance study based on the FAERS database. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1378010

Vancouver

Long P, Li S, Pan L, Wang Y, Chen W, Wang X. Cardiovascular adverse events associated with antibody-drug conjugates (ADCs): a pharmacovigilance study based on the FAERS database. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1378010

BibTeX
@article{Long2024,
  author = {Long, PingPing and Li, Siyu and Pan, Lingyun and Wang, Yuanqiang and Chen, Wanyi and Wang, Xiaoxiao},
  title = {Cardiovascular adverse events associated with antibody-drug conjugates (ADCs): a pharmacovigilance study based on the FAERS database},
  journal = {Frontiers in Pharmacology},
  year = {2024},
  volume = {15},
  doi = {10.3389/fphar.2024.1378010}
}
Kostenlos starten →